SCHEDULE: Purple Biotech Ltd. Ownership Filing

Intracoastal Capital LLC and associated individuals report beneficial ownership of 9.99% of Purple Biotech Ltd. ordinary shares.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Purple Biotech Ltd.
• The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• As of March 31, 2026, the reporting persons collectively hold beneficial ownership of 282,513,535 ordinary shares, representing 9.99% of the class.
• This ownership is derived from the exercise of a warrant held by Intracoastal Capital LLC.
• The filing notes a 'blocker provision' in the warrant that limits exercise to prevent beneficial ownership exceeding 9.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not inherently signal positive or negative performance or strategic shifts for the company.

Positives

• The reporting persons have disclosed their significant beneficial ownership, providing transparency to the market.
• The ownership stake of 9.99% is at the threshold of significant influence, which could be viewed positively by the market if the investors are strategic.

Negatives

• The existence of a blocker provision in the warrant suggests potential limitations or complexities in the reporting persons' ability to increase their stake further without triggering reporting thresholds or regulatory scrutiny.
• The filing does not provide details on the strategic intent behind this ownership stake.

Risks

• Potential for increased scrutiny from regulators due to the significant ownership stake and the presence of a blocker provision.
• Future actions by the reporting persons could impact the company's stock price and control dynamics.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a disclosure of current beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors and significant shareholders crossing certain ownership thresholds. The 9.99% stake reported by Intracoastal Capital LLC and associated individuals is a common level for active investors seeking influence without triggering stricter reporting requirements associated with 10% or more ownership.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership may influence market perception and trading activity.
• Management: May face increased engagement or scrutiny from the reporting persons regarding corporate strategy and performance.

Next Steps

• Monitor future filings from Intracoastal Capital LLC and associated individuals for any changes in beneficial ownership.
• Observe Purple Biotech Ltd.'s corporate actions and strategic decisions for potential influence by these significant shareholders.

Key Dates

Keywords

Purple Biotech Ltd., Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Ordinary Shares, Warrant, SEC Filing